Patent ID: 7147852

Claim:
A method of reducing TGF-β production in a mammal comprising administering to the mammal a composition comprising a zveg3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf3 antagonist is an antibody that specifically binds to a dimeric protein consisting of two polypeptide chains, wherein each of said polypeptide chains consists of a sequence of amino acid residues selected from the group consisting of: residues 230–345 of SEQ ID NO:2; residues 231–345 of SEQ ID NO:2; residues 232–345 of SEQ ID NO:2; residues 233–345 of SEQ ID NO:2; residues 234–345 of SEQ ID NO:2; residues 235–345 of SEQ ID NO:2; residues 236–345 of SEQ ID NO:2; residues 237–345 of SEQ ID NO:2; residues 238–345 of SEQ ID NO:2; residues 239–345 of SEQ ID NO:2; and residues 240–345 of SEQ ID NO:2, in an amount sufficient to reduce TGF-β production.